Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Osteoporosis Drug May Treat Breast and Liver Cancers

Published: Thursday, February 20, 2014
Last Updated: Thursday, February 20, 2014
Bookmark and Share
Study from OSU has shown a drug used to prevent and treat osteoporosis in post-menopausal women may also be able to treat some breast and liver cancers.

Although clinical trials on patients are still needed, in lab tests researchers found that the drug raloxifene, which is marketed under the brand name Evista by Eli Lilly and Co., killed human breast cancer cells that are "triple-negative” as well as liver cancer cells.

Triple-negative breast cancers represent about 15-20 percent of all breast cancers in the United States and are more common in younger and African-American women, according to a factsheet from the Susan G. Komen organization. Chemotherapy, radiation and surgery are the preferred treatments because triple-negative breast cancers don't respond to typical medications like tamoxifen or trastuzumab. That's because their cells lack receptors for estrogen, progesterone and a protein known as human epidermal growth factor receptor 2.

Receptors, which are proteins in or on cells, are like a lock. Hormones act like keys to these receptors to unlock different cellular functions. For example, estrogen causes uncontrolled proliferation of breast cancer cells by binding to a receptor. It's known that raloxifene blocks estrogen from binding to its receptor and thus keeps breast cancer cells from multiplying.

But what OSU researchers discovered is that raloxifene also binds with a protein called the aryl hydrocarbon receptor (AhR) and kills cancer cells that do not have receptors for estrogen, said Ed O’Donnell, a postdoctoral scholar at OSU who conducted the research.

O’Donnell also analyzed survival data on women who had breast cancers that didn't require hormones to fuel the proliferation of the tumor cells. He found an increased survival rate in the women whose breast cancers had higher levels of the AhR protein.

"Our findings are exciting for two reasons," said OSU cancer researcher Siva Kolluri, who led the research, which was published in the journal Cell Death and Disease. "No. 1, our research revealed that we can target a specific protein, the AhR, to potentially develop new drugs for liver cancer and a subset of stubborn breast cancers. That's a major goal of our lab. No. 2, we discovered that raloxifene, a known drug, could potentially be repurposed to treat two distinct types of cancers."

The U.S. Food and Drug Administration approved raloxifene for use in bone loss prevention in post-menopausal women in 1997. In 1999, it was approved for treating postmenopausal women with osteoporosis. In 2007, the agency approved the use of raloxifene for reducing the risk of invasive breast cancer in post-menopausal women with osteoporosis and in post-menopausal women at high risk for invasive breast cancer, which spreads outside the lobules or milk ducts into surrounding breast tissue.

Raloxifene again hit the news in January when the federal government announced that most health insurance plans will be required to offer the prescription medicine at no cost to women who have an increased risk of developing breast cancer.

The OSU research article is called "The Aryl Hydrocarbon Receptor Mediates Raloxifene-induced Apoptosis in Estrogen Receptor Negative Hepatoma and Breast Cancer Cells." It is online at OSU researcher William Bisson was a co-author on the paper.

The research was funded by the American Cancer Society, National Institute of Environmental Health Sciences and the U.S. Department of Defense Breast Cancer Research Program.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Red Wine Antioxidant May Provide New Cancer Therapy Options
Resveratrol and quercetin, two polyphenols that have been widely studied for their health properties, may soon become the basis of an important new advance in cancer treatment,
Monday, July 20, 2015
OSU Researchers Develop new Approach for Studying Tissue Regeneration
Researchers at Oregon State University have shed new light on the process of tissue regeneration in zebrafish.
Tuesday, November 06, 2007
Scientific News
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Biologists Induce Flatworms to Grow Heads and Brains of Other Species
Findings shed light on role of a new kind of epigenetic signaling in evolution, could yield clues for understanding birth defects and regeneration.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
The Secret Behind the Power of Bacterial Sex
Migration between different communities of bacteria is the key to the type of gene transfer that can lead to the spread of traits such as antibiotic resistance, according to researchers at Oxford University.
Farming’s in Their DNA
Ancient genomes reveal natural selection in action.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos